TDO2 and neoplasm: Compared with control LNCaP xenografts, LM10-treated xenografts also significantly reduced the mRNA levels of TDO2, AhR, CYP1A1 and CYP1B1 in castration-recurrent tumours (Fig. 2p; Supplementary Fig. S9c).